The other hand represents a cell working out whether to catch that nanoparticle and then take it, drugs and all, across its protective membrane into its interior. (Source: Wikimedia common) 
Biotechnology

Experts test soft/hard nanocarriers for brain medication delivery

Rizia Bardhan made a fist with one hand then covered it with her other hand, like a baseball player catching a ball in the web of a fielder’s glove.

MedBound Times

The fist represents a special nanocarrier filled with medicine, said the Iowa State University associate professor of chemical and biological engineering. The other hand represents a cell working out whether to catch that nanoparticle and then take it, drugs and all, across its protective membrane into its interior.

Bardhan said that kind of cellular uptake depends on two things: First, the nanoparticle’s surface properties must be acceptable to the cell. There must be the correct ligands, or binders, that will identify the particle as friendly and lock it onto the receiving cell. Then, second, the particle must be the right stiffness–not too soft, not too hard–to be accepted by the cell.

“If it’s too hard, some immune cells will uptake the nanoparticle and clear it out of the cell. (Source: Wikimedia common)
If it’s too soft, it will get stuck in the cell membrane,” Bardhan said. “If it’s too hard, some immune cells will uptake the nanoparticle and clear it out of the cell.
Prof. Bardhan, Associate Professor at Iowa State University.

So, Bardhan and her collaborators have come up with a new approach to making nanocarriers for drug delivery. Their technology features a soft, fat-like, liposome interior (which is already a clinically approved drug carrier) surrounded by a hard shell of gold nanoparticles.

We’re bringing soft and hard together, which is why I call them hybrid nanocarriers,” Bardhan said of the particles that will be no more than 100 billionths of a meter in diameter. “This hard and soft provides a broad range of mechanical properties to achieve high cellular uptake.
Prof. Bardhan, Associate Professor at Iowa State University.
The big idea is to use the hybrid nanocarriers to transport medicine for Alzheimer’s disease, epilepsy, and other disorders across the body’s blood-brain barrier. (Source: Flickr)

The big idea is to use the hybrid nanocarriers to transport medicine for Alzheimer’s disease, epilepsy, and other disorders across the body’s blood-brain barrier, a major hurdle set up by the body to protect the brain from pathogens.

The National Science Foundation is supporting the project with a three-year, $650,000 grant. Bardhan’s three collaborators are all from Iowa State and affiliated with the Nanovaccine Institute based at Iowa State: Donald Sakaguchi, a Morrill Professor of genetics, development, and cell biology; Anwesha Sarkar, an assistant professor of electrical and computer engineering; and Saji Uthaman, a research scientist in chemical and biological engineering.

Sakaguchi will study the nanocarriers in biological models of the blood-brain barrier, Uthaman and Bardhan will synthesize and optimize the nanocarriers, and Sarkar will examine the mechanical properties of the nanocarriers using an atomic force microscope.

An unconventional approach

Bardhan said a major goal of the study will be determining which of the nanocarrier’s mechanical and molecular properties can be manipulated and tuned to efficiently cross the blood-brain barrier.

The researchers will further tune the nanocarriers by using low-level infrared lasers, such as those used by dermatologists, to heat the nanocarriers to fever temperatures, which breaks their membranes and releases their medicine payloads to targeted cells.

All of that would advance “drug delivery in difficult to treat disorders of the brain,” the researchers wrote in a project summary. Bardhan said those disorders could include Alzheimer's disease, Parkinson’s disease, ischemic stroke, epilepsy and seizures.

The researchers wrote that their hybrid, tuned, and targeted approach is creating “unconventional nanocarriers.”

The researchers wrote that their hybrid, tuned, and targeted approach is creating “unconventional nanocarriers.” (Source: Flickr)
Most researchers usually work at the extremes,” Bardhan said. “They’re working with nanoparticles that are either very hard or very soft. The region between is unexplored.
Prof. Bardhan, Associate Professor at Iowa State University.

But it’s a promising place for exploration. As the researchers wrote, “Therapeutic nanocarriers have transformed the landscape of multiple diseases by enabling site-specific drug delivery.” (NR/Newswise)

Download the MedBound app & learn new things everyday!

Diwali Celebrations Turn Toxic: 69% of Families in Delhi Affected by Air Pollution

Suni Lee’s Journey of Triumph: Overcoming Kidney Disease and Defying the Odds to Win Olympic Medals

AIOCD Warns Against Swiggy, PharmEasy’s 10-Minute Medicine Delivery Partnership

NMC Defends Removal of Respiratory Medicine from MBBS Curriculum Amid Court Proceedings

Marylanders To Vote on Expansive ‘Right to Reproductive Freedom’